Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Market Updates - JD Health (06618) rose over 4.5% following a strategic partnership announcement with leading medical device brand Yuyue Medical [1] - Kangfang Biopharma (09926) increased by over 5.7% after receiving NMPA clinical trial approval for its novel tri-specific antibody drug AK150 for treating advanced malignant solid tumors [1] - Yunfeng Financial (00376) saw a significant rise of 14.18%, with a previous day increase of over 10%, amid a temporary suspension announcement related to a major stock price surge [1] - Steel stocks collectively declined, with Asia Pacific Resources (01104) down 7.59% and Maanshan Iron & Steel (00323) down 7.28% [1] Earnings Warnings and Gains - Jiuyuan Group (00827) fell over 20% after issuing a profit warning, projecting a net loss of approximately RMB 709 million for the year ending December 31, 2025, an increase from a loss of RMB 505 million in 2024 [2] - Changfeng Pharmaceutical (02652) surged nearly 43% after announcing that its inhalation powder ICF001 for treating pulmonary arterial hypertension has received NMPA acceptance for clinical trial application [2] - Yicheng Industrial (01596) rose over 76% after announcing a projected net profit of approximately RMB 334 million for the year ending December 31, 2025, compared to a net loss of RMB 57.7 million in 2024 [3] - Akeso Biopharma (09939) increased by over 10.7% following a strategic cooperation agreement with Funo Pharmaceuticals to develop a new cosmetic product [3] Other Notable Movements - Soundon Technology (02495) rose over 5% after projecting a net profit of no less than RMB 120 million for the year ending December 31, 2025, compared to a net loss of RMB 481 million in 2024 [4] - Starry Chain Group (00399) saw an increase of 18.52% after announcing a memorandum of understanding with Newbridge Acquisition Limited for potential acquisition opportunities [4] US Market Highlights - Tencent Holdings (ADR) (TCEHY.US) rose 1.11% as it welcomed Apple's adjustment of App Store commission policies in China [5] - Meta (META.US) fell 3.83%, marking its largest intraday drop since March 6, due to delays in the release of its new AI model [5] - Ulta Beauty (ULTA.US) dropped 14.24% despite strong same-store sales growth, as fourth-quarter profits fell short of expectations [5] - Bitcoin rose over 5% to $73,764, while Ethereum increased over 6.5% to $2,201.41, reflecting a positive trend in the cryptocurrency sector [6]

Core Viewpoint - Akeso, Inc. has announced that its first-in-class trispecific antibody, AK150, has received IND clearance for clinical trials targeting advanced solid tumors, marking a significant advancement in immunotherapy [1] Company Overview - Akeso, Inc. is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust R&D ecosystem centered on its proprietary Tetrabody platform [1] - The company has over 50 innovative assets in its pipeline, with 27 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies and bispecific ADCs [1] Product Details - AK150 is the only trispecific antibody targeting ILT2, ILT4, and CSF1R globally, designed to overcome immunotherapy resistance by addressing the immunosuppressive tumor microenvironment [1] - The antibody works by depleting immunosuppressive myeloid cells and activating CD8+ T cells and NK cells, enhancing the anti-tumor immune response [1] Clinical Significance - AK150 aims to improve anti-tumor efficacy, particularly for "cold tumors," by converting them into "hot tumors" through a multi-target approach [1] - Preclinical studies have shown that AK150 exhibits dose-dependent tumor inhibition across all tested dosage groups, indicating its potential effectiveness [1]

Investment Rating - The industry investment rating is "Overweight" indicating that the industry is expected to outperform the overall market [2][6]. Core Insights - Recent adjustments to the Hong Kong Stock Connect list include companies such as Weili Zhibo and Jinfang Pharmaceutical, effective from March 9. Kangfang Biologics has received clinical approval for its first tri-antibody [2][3]. - Kingsray Biotech anticipates an adjusted net profit of USD 207-242 million for 2025, representing a year-on-year growth of approximately 246.5%-304.3%, primarily due to licensing revenue increasing from USD 2.4 million in 2024 to USD 256-299 million [2][7]. - The Hang Seng Healthcare Index rose by 2.58%, outperforming the Hang Seng Index by 1.02 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Companies like Weili Zhibo, Jinfang Pharmaceutical, and others have been included in the Hong Kong Stock Connect list since March 9. Kangfang Biologics' AK150 has received clinical trial approval for treating advanced malignant solid tumors [3][8]. - Alnylam has initiated a clinical trial for ALN-2232 (ALK7 siRNA) aimed at obesity, with an expected completion date in March 2028 [4][9]. - Agilent Technologies has agreed to acquire Biocare Medical for USD 950 million, enhancing its capabilities in clinical pathology [4][9]. 2. Performance Updates - Kingsray Biotech expects a significant increase in net profit for 2025, while Lepu Biotech anticipates a net profit of no less than RMB 200 million, marking a turnaround [7][8]. - The revenue forecast for Jike Si is projected to decline by 65.6% in 2025, with a net loss of RMB 146 million [7][8]. 3. Recommendations - Focus on innovative drugs with ongoing commercialization and active overseas transactions, particularly companies like BeiGene, Innovent Biologics, and Kangfang Biologics [12]. - In the Pharma sector, companies like 3SBio and Hansoh Pharmaceutical are making strides in their innovative pipelines [12]. 4. Education Sector - The education index increased by 3.1%, outperforming the Hang Seng Index by 0.3 percentage points [14]. - China Oriental Education is recommended due to its strong growth prospects and strategic adjustments in response to vocational training demand [17]. 5. Social Services - Macau's visitor numbers during the Spring Festival reached historical highs, with total inbound travelers at 1.554 million and an average daily visitor count of 173,000, reflecting a year-on-year growth of 5.5% [19].

Core Viewpoint - Kangfang Biopharma presented the final overall survival (OS) results of the HARMONi-A study at the 2025 SITC, demonstrating a statistically significant benefit of Ivonescimab in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC) [1][2][4] Summary by Sections Event - Kangfang Biopharma released the final OS results of the HARMONi-A study, showing a median follow-up of 32.5 months with an OS of 16.8 months for the Ivonescimab group compared to 14.1 months for the control group, achieving an OS hazard ratio (HR) of 0.74 (P=0.019) [1][2] Analysis - The overall data met expectations, with the OS benefit reaching statistical significance. The HARMONi-A study is the first to achieve both progression-free survival (PFS) and OS benefits in this indication, with previous analyses also showing significant PFS results [1][4] - The OS benefit was consistent across subgroups, including patients with and without brain metastases and those with specific EGFR mutations [3] Clinical Development - The HARMONi-A study is the first Phase III trial to show significant clinical benefits in both PFS and OS for EGFR TKI-resistant NSCLC, highlighting the breakthrough potential of Ivonescimab [4] - Global clinical trials for Ivonescimab are accelerating, with new studies initiated for various cancers, including colorectal cancer and NSCLC [5][6] Future Milestones - Upcoming milestones include the submission of a Biologics License Application (BLA) for Ivonescimab in late 2025, along with updates on ongoing clinical trials and new indications [7][8][9] Financial Projections - The company forecasts revenues of 34.42 billion, 51.49 billion, and 76.28 billion for 2025, 2026, and 2027, respectively, with corresponding growth rates of 62.04%, 49.62%, and 48.14% [9]

Core Viewpoint - CITIC Securities reports that Kangfang Biopharma (09926) has multiple products and indications in its pipeline that are expected to be approved for market entry, indicating a strong long-term sustainable development capability [1] Group 1: Pipeline and Product Development - Kangfang Biopharma's research pipeline is expanding, with a rich reserve of early-stage products [1] - The approval of Iwosimab for market entry contributes to the company's sales growth, while the sales revenue from its products is increasing year by year [1] - The company is rated as "Buy" due to the excellent efficacy of its innovative drug products and the broad market potential [1] Group 2: Clinical Trial Results - At the 2025 SITC, Kangfang Biopharma presented the final overall survival (OS) results of the HARMONi-A trial, showing a median follow-up time of 32.5 months, with an OS hazard ratio (OSHR) of 0.74 (0.58-0.95) (P=0.019) for the Iwosimab treatment group compared to the control group [1] - This trial is noted as the first to achieve clinically meaningful and statistically significant benefits in both progression-free survival (PFS) and OS for an immunotherapy in patients with EGFR TKI-pretreated non-small cell lung cancer (NSCLC) [1] Group 3: Future Focus Areas - Future attention can be directed towards the final OS results update for Iwosimab in the domestic HARMONi-2 trial and the submission of the BLA application in the U.S. [2] - Ongoing global clinical trials for AK104 targeting first-line gastric cancer, second-line IO-resistant hepatocellular carcinoma, and PD-L1 negative NSCLC are also noteworthy [2] - The advancement of AK132 (Claudin18.2/CD47), AK137 (CD73/LAG3) into Phase II clinical trials, and the IND application for AK150 (ILT2/ILT4/CSF1R) are significant developments [2]

Investment Rating - The report maintains an "Outperform" rating for the company [2][11]. Core Insights - The company reported a revenue of RMB 2.13 billion in 2024, a decrease of 53.1%, primarily due to a reduction in licensing revenue, while commercial sales revenue increased by 24.9% to RMB 2.00 billion [3][16]. - The company has effectively managed costs, with a significant decline in expense ratios, leading to a narrowed operating net loss of RMB 660 million, down 16.7% year-over-year [4][18]. - The clinical pipeline is advancing steadily, with key programs such as Cadonilimab and Ivonescimab making progress in various clinical trials [5][19]. Financial Performance - Revenue projections for 2025-2027 are RMB 3.41 billion, RMB 5.45 billion, and RMB 7.31 billion, reflecting year-over-year growth of 60% and 34% in subsequent years [11][34]. - The company is expected to turn a profit in 2025, achieving a net profit of RMB 50 million [11][34]. - The gross profit margin is projected to remain high, with estimates of 92.3% in 2025 and 92.9% in 2027 [15]. Clinical Pipeline Progress - Cadonilimab is involved in multiple clinical trials, including adjuvant treatment for hepatocellular carcinoma and combination therapies for non-small cell lung cancer [5][19]. - Ivonescimab is also progressing in various trials, including first-line treatments for biliary tract cancer and head and neck squamous cell carcinoma [20][23]. - The company has several NDA/sNDA approvals expected in 2025, which could significantly impact revenue and market position [9][25]. Cost Management - The company has demonstrated excellent cost management, with R&D expenses decreasing by 5.3% due to the transition of certain clinical research services to in-house execution [4][18]. - Selling expenses grew at a lower rate than commercial sales revenue, resulting in a decline in the selling expense ratio by 5.5 percentage points [4][18]. Valuation - The target price has been adjusted to HKD 96.6 per share based on a DCF model, reflecting a WACC of 10.0% and a perpetual growth rate of 3.0% [11][34].